SPARC and prostate carcinoma: SPARC was shown to be epigenetically silenced in aggressive cells by promoter methylation whereas treatment of prostate cancer cells with the DNA demethylating agent 5-azacytidine (5-AZA) or with the COX2 inhibitor NS398 could restore SPARC expression in malignant prostate cancer cells.